guest ::
| Home > Publications Database > Alpha-synuclein fibrils amplified from multiple system atrophy and Parkinson's disease patient brain spread after intracerebral injection into mouse brain. > print |
| Home > Publications Database > Alpha-synuclein fibrils amplified from multiple system atrophy and Parkinson's disease patient brain spread after intracerebral injection into mouse brain. > print |
| 001 | 263624 | ||
| 005 | 20240112171438.0 | ||
| 024 | 7 | _ | |a pmc:PMC10467043 |2 pmc |
| 024 | 7 | _ | |a 10.1111/bpa.13196 |2 doi |
| 024 | 7 | _ | |a pmid:37485772 |2 pmid |
| 024 | 7 | _ | |a 1015-6305 |2 ISSN |
| 024 | 7 | _ | |a 1750-3639 |2 ISSN |
| 024 | 7 | _ | |a altmetric:151930620 |2 altmetric |
| 037 | _ | _ | |a DZNE-2023-00843 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Zhang, Shuyu |0 0000-0001-7645-5448 |b 0 |
| 245 | _ | _ | |a Alpha-synuclein fibrils amplified from multiple system atrophy and Parkinson's disease patient brain spread after intracerebral injection into mouse brain. |
| 260 | _ | _ | |a Oxford |c 2023 |b Wiley-Blackwell |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1694171444_31830 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Parkinson's disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB) are neurodegenerative disorders with alpha-synuclein (α-syn) aggregation pathology. Different strains of α-syn with unique properties are suggested to cause distinct clinical and pathological manifestations resulting in PD, MSA, or DLB. To study individual α-syn spreading patterns, we injected α-syn fibrils amplified from brain homogenates of two MSA patients and two PD patients into the brains of C57BI6/J mice. Antibody staining against pS129-α-syn showed that α-syn fibrils amplified from the brain homogenates of the four different patients caused different levels of α-syn spreading. The strongest α-syn pathology was triggered by α-syn fibrils of one of the two MSA patients, followed by comparable pS129-α-syn induction by the second MSA and one PD patient material. Histological analysis using an antibody against Iba1 further showed that the formation of pS129-α-syn is associated with increased microglia activation. In contrast, no differences in dopaminergic neuron numbers or co-localization of α-syn in oligodendrocytes were observed between the different groups. Our data support the spreading of α-syn pathology in MSA, while at the same time pointing to spreading heterogeneity between different patients potentially driven by individual patient immanent factors. |
| 536 | _ | _ | |a 352 - Disease Mechanisms (POF4-352) |0 G:(DE-HGF)POF4-352 |c POF4-352 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a Mice |2 MeSH |
| 650 | _ | 2 | |a alpha-Synuclein: metabolism |2 MeSH |
| 650 | _ | 2 | |a Parkinson Disease: pathology |2 MeSH |
| 650 | _ | 2 | |a Multiple System Atrophy: pathology |2 MeSH |
| 650 | _ | 2 | |a Brain: pathology |2 MeSH |
| 650 | _ | 2 | |a Synucleinopathies: pathology |2 MeSH |
| 650 | _ | 2 | |a Antibodies |2 MeSH |
| 650 | _ | 7 | |a Snca protein, mouse |2 NLM Chemicals |
| 650 | _ | 7 | |a Parkinson's disease |2 Other |
| 650 | _ | 7 | |a alpha-synuclein |2 Other |
| 650 | _ | 7 | |a microglia |2 Other |
| 650 | _ | 7 | |a multiple system atrophy |2 Other |
| 650 | _ | 7 | |a patient-derived fibrils |2 Other |
| 650 | _ | 7 | |a alpha-Synuclein |2 NLM Chemicals |
| 650 | _ | 7 | |a Antibodies |2 NLM Chemicals |
| 700 | 1 | _ | |a Dauer, Karina |b 1 |
| 700 | 1 | _ | |a Strohäker, Timo |0 P:(DE-2719)2812850 |b 2 |
| 700 | 1 | _ | |a Tatenhorst, Lars |0 P:(DE-2719)2812849 |b 3 |u dzne |
| 700 | 1 | _ | |a Caldi Gomes, Lucas |0 0000-0003-4959-2169 |b 4 |
| 700 | 1 | _ | |a Mayer, Simon |b 5 |
| 700 | 1 | _ | |a Jung, Byung Chul |b 6 |
| 700 | 1 | _ | |a Kim, Woojin S |b 7 |
| 700 | 1 | _ | |a Lee, Seung-Jae |b 8 |
| 700 | 1 | _ | |a Becker, Stefan |b 9 |
| 700 | 1 | _ | |a Liesche-Starnecker, Friederike |0 0000-0003-1948-1580 |b 10 |
| 700 | 1 | _ | |a Zweckstetter, Markus |0 P:(DE-2719)2810591 |b 11 |
| 700 | 1 | _ | |a Lingor, Paul |0 P:(DE-2719)2812561 |b 12 |u dzne |
| 773 | _ | _ | |a 10.1111/bpa.13196 |g Vol. 33, no. 5, p. e13196 |0 PERI:(DE-600)2029927-8 |n 5 |p e13196 |t Brain pathology |v 33 |y 2023 |x 1015-6305 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/263624/files/DZNE-2023-00843.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/263624/files/DZNE-2023-00843.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:263624 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 2 |6 P:(DE-2719)2812850 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 3 |6 P:(DE-2719)2812849 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 11 |6 P:(DE-2719)2810591 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 12 |6 P:(DE-2719)2812561 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-352 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Mechanisms |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2022-09-26T13:10:13Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2022-09-26T13:10:13Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2022-09-26T13:10:13Z |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BRAIN PATHOL : 2022 |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-24 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-24 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b BRAIN PATHOL : 2022 |d 2023-10-24 |
| 920 | 1 | _ | |0 I:(DE-2719)1410001 |k AG Zweckstetter |l Translational Structural Biology |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1410001 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|